AI assistant
Dyne Therapeutics, Inc. — Director's Dealing 2021
Dec 14, 2021
31790_dirs_2021-12-14_052bf6e7-0784-4bd9-b6d0-b4692005d493.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Dyne Therapeutics, Inc. (DYN)
CIK: 0001818794
Period of Report: 2021-12-10
Reporting Person: Farwell Wildon (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-12-10 | Common Stock | A | 22307 | $0.00 | Acquired | 72307 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-12-10 | Stock Option (right to buy) | $13.12 | A | 67935 | Acquired | 2031-12-09 | Common Stock (67935) | Direct |
Footnotes
F1: Consists of shares of Common Stock issuable under 22,307 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022.
F2: Includes 72,307 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting.
F3: This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025.